Announcement
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 11 Sep - Rainbow Children’s schedules analyst/institutional investor meetings on September 18, 21 and 22, 2026 in Mumbai.
Source: Bse
Rainbow Childrens Medicare Limited (RAINBOW)
Large CapPharma stocks · Large cap · NSE
Rainbow Children's Medicare is India's largest pediatric hospital chain with 24 hospitals and 5 clinics across 9 cities. It offers comprehensive pediatric, perinatal, and fertility care, operating on a hub-and-spoke model with a full-time consultant-led service. The company has a total bed capacity of 2,435.
Data qualityFresh enough for analysisQuote updated 21 Oct, 04:45 am ISTDetails
Quote21 Oct, 04:45 am IST
Base fundamentals14 Oct 2026 · screener
Latest result30 Jul, 09:57 pm IST
Score21 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags02 May 2026
Coverage14/14 · 100%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
57NeutralSMA20 -10.0% / mo · MACD − · sector +3.8pp vs Nifty 500 (3M)
Stock trend: 29
Sector RS: 98
Sector 3M: -1.8% vs Nifty 500 -5.6%
Pharma FPI tailwindFlow only
FPI equity flow was positive in both fortnights, but the sector index is below its 100-session average. View sector evidence
Technical chart
RAINBOWD candles · FIT view-0.5%Latest close ₹1236.00 on 2026-10-19
Bar
-0.7%
RSI
32
MACD hist
-0.87
52W pos
29%
2026-10-19O ₹1245.30H ₹1260.00L ₹1229.80C ₹1236.00Vol 59,031 sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
RAINBOWNifty PharmaNifty 500
- RAINBOW
- -17.2%
- Nifty 500
- -5.6%
- Nifty Pharma
- -1.5%
- Vs Nifty 500
- -11.6 pp
Chart stats
19 Oct 2026- From 52W high
- -23.2%
- 52W range position
- 29%
- ATR (14)
- 3.5%
- Volume vs 20D
- 0.31x
- Avg traded value
- ₹24.6 Cr
- 20D price channel
- ₹1,196.8 - ₹1,454.6
₹1,610
₹1,084 - ₹1,610
₹43.4
Latest completed session
20-session average
27.8% annualized volatility
Research snapshot
What the evidence says now
Mixed fundamentals, management evidence is still limited to a financial-only Trust Lite signal, price trend is neutral, and recent execution is consistent.
Suggested next step
Research, do not rush
The evidence is not strongly aligned. Compare peers and wait for a cleaner setup.
U-Score
Legacy · FAIR VALUE49
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Average42
Revenue +33.1% · PAT +16.7% YoY
Technical
Neutral57
Price trend and sector-relative-strength timing.
Valuation
Legacy model+2.2%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence76
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Average · 42/100margin compression · Rev +33% YoY · PAT +17% YoY
Filed 30 Jul 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹470 Cr | +33.1% | +2.2% |
| EBITDA | ₹135 Cr | +29.8% | -6.9% |
| Operating margin | 29.0% | +0 bps | -200 bps |
| PAT | ₹63 Cr | +16.7% | -19.2% |
| PAT margin | 13.4% | -190 bps | -356 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 44.50
- P/B
- 7.75
- EV/EBITDA
- 18.57
- Market Cap
- 12743.00Cr
Profitability
- ROE
- 15.90%
- ROCE
- 17.40%
- ROA
- 10.45%
- Dividend Y
- 0.28%
Growth (CAGR)
- Revenue 5Y
- 21.00%
- EPS 5Y
- 44.00%
- Revenue 3Y
- 13.00%
- EPS 3Y
- 6.00%
Balance Sheet
- Debt/Equity
- 0.54
- Interest Coverage
- 7.10×
- Altman Z
- 8.33
- Book Value
- 162.00
Cash Flow
- FCF Yield
- 1.26%
- FCF Positive Y
- 10/5
- OCF
- 420.00 Cr
- EPS TTM
- 28.10
Shareholding
- Promoter Hold
- 49.84%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 41%
Financial History
Updated 20/10/2026
Revenue
₹ CrLatest: 1,703+12.3% vs prev
Net Profit
₹ CrLatest: 282+15.6% vs prev
Return on Equity
%Latest: 17.1+3.0% vs prev
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Mixed signalsSignals are conflicting — long-term trend down. RSI 32. Wait for confirmation.
- Price below SMA200 (long-term downtrend) — short-term bounces likely countertrend.
- SMA20 falling (~11.1% over last month) — short-term momentum negative.
- RSI(14) at 32 — rising, no extreme reading.
- MACD below signal but histogram contracting — bearish momentum easing.
- 23% off 52W high · 14% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
45
RS percentile
Stage 1 Base / Transition
1M return
-15.0%
3M return
-17.2%
6M return
-4.5%
1Y return
-10.2%
RS 1D
-1
RS 20D
-22
Sector rank
#1
Industry rank
#12
Stage evidence
- Price is 9.6% below the 30-week proxy without full trend alignment.
- The 30-week proxy changed +1.2% over 20 sessions.
- The moving-average structure does not confirm Stage 2 or Stage 4.
50-DMA
price below
200-DMA
price below
Sector
leading
Industry
weakening
Relative-strength line vs Nifty 500 (base 100)
261 observations
19 Oct 2026Value 95.12-0.01%
RS vs Nifty 50095
Valuation & peers
U-Score 49 · legacy U-Score band FAIR VALUE · valuation evidence and comparable companies
Valuation & peers
U-Score 49 · legacy U-Score band FAIR VALUE · valuation evidence and comparable companies
Financial Turnaround
Fundamental score breakdown
U band · FAIR VALUEValuation2/30
Growth17/25
Quality11/20
Balance Sheet7/15
Cash Flow7/10
Piotroski
8/9 (+5)
Penalties
0
Raw sum
49
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
49/100 · legacy band FAIR VALUE
Positive drivers
- Piotroski is strong at 8/9.
- Cash flow contributes 7/10 to the score.
- Growth contributes 17/25 to the score.
Main drags
- Valuation is weaker at 2/30; verify the latest quarterly trend.
- Balance sheet is weaker at 7/15; verify the latest quarterly trend.
- Quality is weaker at 11/20; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
44.5
PB
7.8
EV/EBITDA
18.6
ROE
15.9%
ROCE
17.4%
FCF Yield
1.3%
Debt/Equity
0.5
MoS
+2.2%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 21 Oct 2026
v4.3-runtime-valuation
Final score
49
Previous: 49
Legacy U-Score band
FAIR VALUE
Previous: FAIR VALUE
Margin of safety
+2.2%
Previous: +2.2%
Score history
12 stored score snapshots. Latest stored move: +0 points.
21 Oct 2026
v4.3-runtime-valuation
49
49
49
49
49
49
49
49
49
49
49
49
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹320.04
-286.2% MoS
Growth-justified P/E
45.0
Growth-justified Value
₹1,264.5
+2.2% MoS
PEG
1.55
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
VIJAYA
Large
Vijaya Diagnostic Centre Limited
Healthcare Services
match 166
43
76.2
18.3%
-67%
WATCHLIST
JUBLPHARMA
Large
Jubilant Pharmova Limited
Healthcare Services
match 164
24
38.5
6.5%
-1190%
OVERVALUED
ONESOURCE
Large
Onesource Specialty Pharma Limited
Healthcare Services
match 163
27
310.0
0.5%
-632%
OVERVALUED
SUDEEPPHRM
Micro
Sudeep Pharma Limited
Healthcare Services
match 161
49
65.4
25.2%
-32%
FAIR VALUE
MARKSANS
Micro
Marksans Pharma Limited
Healthcare Services
match 161
53
27.3
15.2%
+41%
FAIR VALUE
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Where growth can come from, and what can break the case
Thesis intactReviewed 2026-06-03T18:27:29.527Z
Management commentary snapshot
Q4 FY26 Revenue grew 24% YoY to INR 4,599 Mn, with PAT up 38% YoY to INR 782 Mn, driven by new hospital commencements and increased operational beds. FY26 Revenue rose 12% YoY, PAT 15% YoY. Overall occupancy declined slightly YoY for both Q4 and FY26.
The company demonstrates strong financial growth, leveraging its hub-and-spoke model and new capacity additions. However, the slight decline in overall occupancy, particularly in mature hospitals, suggests potential dilution from new, ramping-up facilities. Sustained growth hinges on efficient ramp-up of new beds and maintaining utilization in existing ones.
Current business mix
Inpatient Income Payor Profile (Q4 FY26)
Latest issuer-disclosed distribution across 2 reported categories.
Cash47.5%
Insurance52.5%
Growth engines
Hub-and-Spoke Expansion
Replicating successful hub-and-spoke model in Chennai and NCR, with plans to expand into Tier-2 cities of Southern India.
New Hospital Commencements
Commenced new 60-bed HRBR Hospital and a dedicated IVF centre at Mahadevapura, Bengaluru, strengthening network.
Comprehensive Care
Offers a full suite of pediatric, perinatal, and fertility services, including quaternary care and advanced fetal medicine.
Doctor Engagement Model
Unique full-time, retainer-based doctor model ensures 24/7 consultant-led care, fostering high retention and loyalty.
Capacity and execution
HRBR Hospital, Bengaluru
New 60-bed hospital commenced operations from May 1, 2026.
Mahadevapura IVF Centre, Bengaluru
Dedicated ~10,000 sq. ft. IVF centre commenced operations.
Coimbatore
~130 beds expected to be commissioned by H2 FY27-28.
Gurugram (Sector 44 & 56)
~325 beds planned for Sector 44 in FY27-28 and ~125 beds for Sector 56 in FY28-29.
Risk radar
Occupancy Dilution
Overall occupancy declined to 45.3% in Q4 FY26 (-3% YoY) and 46.3% in FY26 (-8% YoY), with mature hospitals also seeing a drop.
New Hospital Ramp-up
New hospitals, including recent acquisitions and commencements, require time to achieve optimal occupancy and profitability, impacting overall utilization.
Management accountability
What management said, and what results must prove
Issuer guidance and extracted claims are tracked against later reported outcomes. Treat these as management statements, not IndiaPulse forecasts.
Analyst reading lens
Compare BOTH
Q4 results show both sequential momentum (QoQ) and annual growth (YoY), which are relevant for assessing recent operational trends and overall annual performance. FY26 results are best read YoY for full-year comparison.
Sector KPIs management disclosed
Operational Beds
Q4 FY26: 2,375 (+23% YoY); FY26: 2,375 (+23% YoY).
Occupancy
Q4 FY26: 45.3% (-3% YoY); FY26: 46.3% (-8% YoY). Mature hospitals occupancy: Q4 FY26: 51.8% (+2% YoY); FY26: 51.0% (-9% YoY).
IP Discharges
Q4 FY26: 27,165 (+18% YoY); FY26: 104,514 (+6% YoY).
OP Consultations
Q4 FY26: 424,702 (+19% YoY); FY26: 1,598,970 (+12% YoY).
Management forward view
Expansion Strategy
Management aims to replicate the hub-and-spoke model in Chennai and NCR, and expand into Tier-2 cities of Southern India.
Integrated Services
Committed to providing comprehensive women and child healthcare, with synergies between pediatric and perinatal services.
Quality & Training
Pioneering the largest pediatric DNB training program in private healthcare, recognized as MRCPCH Examination Centre.
Thesis monitor
Numbers and claims to verify in the next filings
| Checkpoint | Current evidence | What to verify next |
|---|---|---|
| Overall Occupancy | 46.3% (FY26) | Stabilization and improvement, especially in new hospitals, to drive revenue growth. |
| New Hospital Ramp-up | 11 hospitals under 5 years of operations | Occupancy and profitability trends in these new facilities to assess successful integration. |
| ARPOB | INR 60,141 (FY26) | Sustained growth, indicating pricing power and favorable case mix. |
| Expansion Timelines | Coimbatore (H2 FY27-28), Gurugram (FY27-28, FY28-29), Pune (FY28-29) | Adherence to commissioning schedules for planned capacity additions. |
Verification checkpoints are IndiaPulse research interpretation, not investment advice.
Show extracted source claims
project executionnot yet verifiablequantified
The Hennur (Bengaluru) facility (~60 beds) is expected to commence operations by January 2026, subject to approvals.
Timeframe: by January 2026Direction: commencementConfidence: expected
"expected to commence operations by January 2026, subject to approvals"
project executionnot yet verifiablequantified
The regional hub hospital at Coimbatore (~130 beds) is expected to be ready by the end of FY27.
Timeframe: by the end of FY27Direction: completionConfidence: expected
"expected to be ready by the end of FY27"
capex timelinenot yet verifiable
All planned capital expenditures will be completed through internal accruals without any debt financing.
Timeframe: coming yearsDirection: completion without debtConfidence: confident
"complete all planned capital expenditures through internal accruals without any debt financing"
revenue outlookdelivered
Prashanthi hospital in Warangal and Pratiksha hospital in Guwahati are expected to see an uptick in revenue from December onwards.
Timeframe: from December onwardsDirection: uptickConfidence: expect
"we expect to see an uptick from December onwards"
Outcome check: Revenue YoY averaged 11.8% across 1 later quarter(s).
Trust Score
76Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Management has 100% delivered/partly-delivered outcomes on 1 checked claims. It ranks around the 81st percentile of the scored universe and 73rd percentile within Pharma. No major sub-score weakness stands out.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 21 Oct 2026
management-trust-v1
84 docs text-extracted · 37 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
81st percentile
overall median 67 · Pharma: 73rd pctile, median 70 · Large: 62nd pctile, median 73
Evidence depth
Financial-only
84 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
100% delivered or partly delivered
1/4 claims checked · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Can support position sizing if valuation and trend also agree.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
78
strong · holding, pledge, alignment
Cash flow
77
strong · profit to cash conversion
Balance sheet
81
strong · leverage and solvency
Discipline
60
acceptable · capital discipline
Results
87
strong · quarterly consistency
Trust positives
- ▸Promoter pledge is zero.
- ▸FCF yield is positive at 1.3%.
- ▸10 years of positive FCF.
- ▸4/4 latest quarters had positive YoY revenue growth.
Trust risks
- ▸No major Trust Lite risk flags.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Rainbow Childrens Medicare Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 27 Jun - Information regarding 28th Annual General Meeting.
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS 25 Jun
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 25 May
Source: Bse
Annual report
Annual Report 2026
Source: Bse
Annual report
Annual Report 2025
Source: Bse
Annual report
Announcement under Regulation 30 (LODR)-Newspaper Publication 5 Jul - Intimation for Newspaper Publication for dispatch of Notice of 28th Annual General Meeting and Integrated Annual report for the Financial year 2025-26.
Source: Bse
Annual report
Intimation Of Dispatch Of Letter Containing QR Code And Web-Link To Access The Integrated Annual Report For FY 2025-26 4 Jul - FY2025-26 Integrated Annual Report web link and QR code shared with shareholders lacking registered email IDs.
Source: Bse
Annual report
Reg. 34 (1) Annual Report. 4 Jul - Rainbow Children’s Medicare filed its Integrated Annual Report for FY 2025-26.
Source: Bse
Annual report
Notice Convening The 28Th Annual General Meeting And Integrated Annual Report For The Financial Year 2025-26 4 Jul
Source: Bse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.